Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06775912 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Jan 15, 2025 to Jan 3, 2025v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG
Trial Details
NCT Number NCT06775912
Lead Sponsor Nanjing Bioheng Biotech Co., Ltd.
Conditions
(from sponsor)		 SLE, Systemic Sclerosis, IIM, NMOSD, MS, MG, ANCA Associated Vasculitis (AAV)
Related terms Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Scleroderma, Systemic
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov